Paclitaxel in combination with weekly 24-hour infusional 5-fluorouracil plus leucovorin in the second-line treatment of metastatic breast cancer: Results of a phase II study

Annals of Oncology

Volumn 9, Issue 1, 1998, Pages 45-50

  Klaassen, U ^a   Wilke, H ^a   Harstrick, A ^a   Philippou Pari, C ^a   Strumberg, D ^a   Neumann, K ^a   Eberhardt, W ^a   Achterrath, W ^a   Lenaz, L ^a   Seeber, S ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Metastatic breast cancer; Paclitaxel; Weekly 24 hour 5 FU leucovorin

Indexed keywords

ANTHRACYCLINE; FLUOROURACIL; FOLINIC ACID; PACLITAXEL;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MIDDLE AGED; PACLITAXEL; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 6844249418     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008292332166     Document Type: Article

References (23)

1. Honig SF. Treatment of melastatic disease: Hormonal therapy and chemotherapy. In Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast. New York: Lippencott-Raven 1996; 669-734.
2. Swain SM, Lippman ME, Egan EF et al. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 890-9.
3. Hansen R, Quebbeman E, Beatty P et al. Continuous 5-fluorouracil infusion in refractory carcinoma of the breast. Breast Cancer Res treat 1987; 10: 145-9.
4. Doroshow JH, Leong L, Margolin K et al. Refractory metastatic breast cancer: Salvage therapy with fluorouracil and high dose continuous infusion leucovorin calcium. J Clin Oncol 1989; 7: 439-44.
5. Marini G, Simoncini E, Zaniboni A et al. 5-fluorouracil and high dose folinic acid as salvage treatmenl of advanced breast cancer: An update. Oncology 1989; 44: 336-40.
6. Loprinzi CL. 5-fluorouracil with leucovorin in breast cancer. Cancer 1989; 63: 1045-7.
7. Houghton JA, Schmidt C, Houghton PJ. The effect of derivatives of folic acid on the fluorodeoxyuridylate-thymidilate synthetase covalent complex in human colon xenografts. Eur J Cancer Clin oncol 1982; 18: 347-54.
8. Yin MB, Zakrzewski SF, Hakala MT. Relationship of cellular folate cofactor pools to the activity of 5-fluorouracil. Mol Pharmacol 1983; 23: 190-7.
9. Evans RM, Laskin JD, Hakala MT. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981; 41: 3288-95.
10. Petrelli N, Herrera L, Rustum YM et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559-65.
11. Machover D, Goldschmidt E, Chollet P et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 1986; 4: 685-96.
12. Köhne-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM. Chemotherapeutic strategies in metastatic colorectal cancer: An overview of current clinical trials. Semin Oncol 1992; 19 (Suppl 3): 105-25.
13. Wilke H, Klaassen U, Achterrath Wet al. Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 1996; 7: 55-8.
14. Nabholtz JM, Gelmon K, Bontenbal M et al. A multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996; 14: 1858-67.
15. Holmes FA, Walters RS, Theriault RL et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-1805.
16. Gianni L, Capri G, Munzone E, Straneo M. Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 1994; 21 (Suppl 8): 29-33.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
18. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of rsistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52: 1855-64.
19. Harstrick A, Gonzales A, Hoffmann A et al. Development and characterisation of human gastric, colon abd breast carcinoma cell lines resistant to 5-FU using various, clinically relevant application schedules. Proc Am Assoc Cancer Res 1995; 36: 317 (Abstr 1889).
20. Smith IE. Continuous infusional 5-fluorouracil in breast cancer or the revival of an old drug? Ann Oncol 1996; 7: 771-2.
21. Regazzoni S, Pesce G, Marini G et al. Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer. Ann Oncol 1996; 7: 807-13.
22. Lokich J, Anderson N. Dose intensity for bolus versus infusion chemotherapy administration: Review of the literature for 27 antineoplastic agents. Ann Oncol 1996; 8: 15-25.
23. Osborne CK, Clark GM, Ravdin PM. Adjuvant systemic therapy of primary breast cancer. In Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast. Philadelphia, New York: Lippencott-Raven 1996; 548-78.